In conclusion, we demonstrated that TACE-activity inhibition by Marimastat in two murine models of hepatic steatosis resulted in reversal of steatosis, coupled with improvement of surrogate markers of insulin sensitivity. The gene discussed is ADAM17; the disease is Hepatic steatosis.